(Q42713576)

5 November 2017

title

Activity-based kinase profiling of approved tyrosine kinase inhibitors (English)

1 reference

5 November 2017

Daisuke Kitagawa

1

1 reference

5 November 2017

Koichi Yokota

2

1 reference

5 November 2017

Masaki Gouda

3

1 reference

5 November 2017

Yugo Narumi

4

1 reference

5 November 2017

Hiroshi Ohmoto

5

1 reference

5 November 2017

Eiji Nishiwaki

6

1 reference

5 November 2017

Kensaku Akita

7

1 reference

5 November 2017

Yasuyuki Kirii

8

1 reference

5 November 2017

publication date

26 December 2012

1 reference

5 November 2017

1 reference

5 November 2017

volume

18

1 reference

5 November 2017

issue

2

1 reference

5 November 2017

page(s)

110-122

1 reference

SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer

5 November 2017

cites work

1 reference

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

21 January 2018

1 reference

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies

21 January 2018

1 reference

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

21 January 2018

1 reference

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture.

21 January 2018

1 reference

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo

21 January 2018

1 reference

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases

21 January 2018

1 reference

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

21 January 2018

1 reference

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

21 January 2018

1 reference

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity

21 January 2018

1 reference

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

21 January 2018

1 reference

Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase

21 January 2018

1 reference

Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.

21 January 2018

1 reference

Features of selective kinase inhibitors

21 January 2018

1 reference

c-kit is required for cardiomyocyte terminal differentiation

21 January 2018

1 reference

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

21 January 2018

1 reference

The protein kinase complement of the human genome

21 January 2018

1 reference

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

21 January 2018

1 reference

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

21 January 2018

1 reference

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

21 January 2018

1 reference

Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis

21 January 2018

1 reference

The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain

21 January 2018

1 reference

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia

21 January 2018

1 reference

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice

21 January 2018

1 reference

Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/GTC.12022

1 reference

5 November 2017

1 reference